Doctor Juan Francisco Cortes Benítez is a Professor at the Universidad Autónoma Metropolitana (UAM) Xochimilco Campus. He has more than ten years of experience acquired at the academic level for the design and synthesis of molecules with pharmacological activity, as well as two years at the industrial level focused on the organic synthesis of bioactive compounds both at the laboratory level and scaling up in production plants.
He studied for a degree in Pharmaceutical Chemist Biologist (2011) at the Faculty of Chemistry of the Universidad Nacional Autónoma de México (UNAM). He also obtained a Master's degree (2013) and later a Ph.D. in Chemical Sciences (2017), both with honorable mention from the same university.
Additionally, he has done a research stay for one year at the "Centre hospitalier de l'Université Laval" in the city of Quebec in Canada, where he focused on the design and organic synthesis of steroidal derivatives for the treatment of prostate cancer, mainly.
Currently, he is in charge of two research projects focused on the design (through molecular docking and molecular dynamics studies), organic synthesis, and biological evaluation of new molecules for the simultaneous treatment of type 2 diabetes mellitus and obesity.
Doctor Juan Francisco Cortes Benítez is a Professor at the Universidad Autónoma Metropolitana (UAM) Xochimilco Campus. He has more than ten years of experience acquired at the academic level for the design and synthesis of molecules with pharmacological activity, as well as two years at the industrial level focused on the organic synthesis of bioactive compounds both at the laboratory level and scaling up in production plants.
He studied for a degree in Pharmaceutical Chemist Biologist (2011) at the Faculty of Chemistry of the Universidad Nacional Autónoma de México (UNAM). He also obtained a Master's degree (2013) and later a Ph.D. in Chemical Sciences (2017), both with honorable mention from the same university.
Additionally, he has done a research stay for one year at the "Centre hospitalier de l'Université Laval" in the city of Quebec in Canada, where he focused on the design and organic synthesis of steroidal derivatives for the treatment of prostate cancer, mainly.
Currently, he is in charge of two research projects focused on the design (through molecular docking and molecular dynamics studies), organic synthesis, and biological evaluation of new molecules for the simultaneous treatment of type 2 diabetes mellitus and obesity.